4.8 Article

Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 120, 期 12, 页码 4532-4545

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI43961

关键词

-

资金

  1. NIH [1R01AI083201-01, 1R01NS065845-01]
  2. National Foundation for Science, Higher Education and Technological Development of the Republic of Croatia [04/16]
  3. S Jonjic and Croatian Ministry for Science and Technology [0621261-1268]
  4. Howard Hughes Medical Institute

向作者/读者索取更多资源

Human CMV (HCMV) is a major cause of morbidity and mortality in both congenitally infected and immunocompromised individuals. Development of an effective HCMV vaccine would help protect these vulnerable groups. NK group 2, member D (NKG2D) is a potent activating receptor expressed by cells of the innate and adaptive immune systems. Its importance in HCMV immune surveillance is indicated by the elaborative evasion mechanisms evolved by the virus to avoid NKG2D. In order to study this signaling pathway, we engineered a recombinant mouse CMV expressing the high-affinity NKG2D ligand RAE-1 gamma (RAE-1 gamma MCMV). Expression of RAE-1 gamma by MCMV resulted in profound virus attenuation in vivo and lower latent viral DNA loads. RAE-1 gamma MCMV infection was efficiently controlled by immunodeficient hosts, including mice lacking type I interferon receptors or immunosuppressed by sublethal gamma-irradiation. Features of MCMV infection in neonates were also diminished. Despite tight innate immune control, RAE-1 gamma MCMV infection elicited strong and long-lasting protective immunity. Maternal RAE-1 gamma MCMV immunization protected neonatal mice from MCMV disease via placental transfer of antiviral Abs. Despite strong selective pressure, the RAE-1 gamma transgene did not exhibit sequence variation following infection. Together, our results indicate that use of a recombinant virus encoding the ligand for an activating NK cell receptor could be a powerful approach to developing a safe and immunogenic HCMV vaccine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据